Both studies, whose results were announced in separate press releases, met their primary endpoints.
In the first study, the drug candidate admilparant achieved a statistically significant improvement in lung function compared with placebo after 52 weeks in patients with idiopathic pulmonary fibrosis (IPF).
BREAKING